Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer

Robin M. J. M. van Geel, Emilie M. J. van Brummelen, Ferry A. L. M. Eskens, Sanne C. F. A. Huijberts*, Filip Y. F. L. de Vos, Martijn P. J. K. Lolkema, Lot A. Devriese, Frans L. Opdam*, Serena Marchetti, Neeltje Steeghs, Kim Monkhorst, Bas Thijssen, Hilde Rosing, Alwin D. R. Huitema, Jos H. Beijnen, Rene Bernards, Jan H. M. Schellens

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

6 Citations (Web of Science)
Original languageEnglish
Pages (from-to)1166-1174
Number of pages9
JournalBritish Journal of Cancer
Issue number8
Publication statusPublished - Apr 2020


  • RAS
  • ARRY-142886
  • AZD6244

Cite this